from Reuters: Health News https://ift.tt/2Nnd9ma
via IFTTT
Monday, January 13, 2020
AstraZeneca to discontinue Epanova trial, expects $100 million writedown
AstraZeneca said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million writedown to hit its core profit in the fourth quarter.
from Reuters: Health News https://ift.tt/2Nnd9ma
via IFTTT
from Reuters: Health News https://ift.tt/2Nnd9ma
via IFTTT
0 comments:
Post a Comment